Clinical Trials
68 trialsOpen-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
PROACT
Washington University School of Medicine
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
TrRaMM-TMI
IRCCS San Raffaele
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Mirror Biologics, Inc.
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
National Institutes of Health Clinical Center (CC)
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Alexion Pharmaceuticals, Inc.
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Massachusetts General Hospital
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Massachusetts General Hospital
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
A Phase II Study of Umbilical Cord Blood Transplantation
Tufts Medical Center
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
The Cleveland Clinic
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Rutgers, The State University of New Jersey
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
University of Rochester
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
Case Comprehensive Cancer Center
Efficacy of a Patient Education Video
Virginia Commonwealth University
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
City of Hope Medical Center
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
Vanderbilt University
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute